查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1516708

高三酸甘油脂血症 (HTG) 的全球市場管道

Global Hypertriglyceridemia Market Pipeline
出版日期: | 出版商: Inkwood Research | 英文 295 Pages | 商品交期: 2-3個工作天內

價格

主要發現

高三酸甘油脂血症（HTG）是一種以血液中三酸甘油酯含量高為特徵的疾病。三酸甘油酯是脂肪的一種，從飲食中獲取並由身體產生。三酸甘油酯水平升高會使您面臨心臟病和中風等心血管疾病的風險。

此外，高三酸甘油脂血症（HTG）與肥胖、不受控制的糖尿病、甲狀腺功能減退、肝臟和腎臟疾病以及某些遺傳性疾病有關。高脂肪飲食、過度飲酒和缺乏運動等生活習慣會增加三酸甘油酯水平。治療包括飲食改變、體重管理、規律運動和必要時藥物治療。

市場洞察

全球高三酸甘油脂血症（HTG）市場的關鍵成長因素

  • 提高對高三酸甘油脂血症（HTG）的認識
  • 高三酸甘油脂血症 (HTG) 盛行率增加
  • 擴大治療選擇

高三酸甘油酯血症 (HTG) 可以透過改變生活方式來控制，例如減少脂肪和碳水化合物的攝取、限制飲酒、戒菸和定期運動。

此外，他汀類藥物和貝特類藥物等治療方法已被用來降低三酸甘油酯（TG）水平。目前，治療高三酸甘油脂血症（HTG）的主要藥物是他汀類藥物和貝特類藥物。然而，有些患者可能不適合這些治療或可能對這些治療沒有反應。

為了彌補這一差距，各公司正在努力開發新的治療方法，旨在更有效地降低血液中的三酸甘油酯並減輕高三酸甘油酯血症 (HTG) 的影響。特別是，針對載脂蛋白 C-III 和 ANGPTL 的方法已被廣泛探索。

同時，基於載脂蛋白C-III的新藥也顯示出可喜的結果，預計將在不久的將來上市。這種創新療法的推出有可能顯著推進 HTG 管理，並為對目前治療有抗藥性的患者提供更好的選擇。

全球高三酸甘油脂血症（HTG）市場的主要成長限制因素

  • 開發新療法遇到挫折

高三酸甘油脂血症治療藥物和產品的開發在早期和後期的臨床試驗中失敗率很高。

同時，Pfizer和 Ionis 最近停止了其 III 期藥物 Vaupanorsen，因為 II 期結果不足以證明繼續臨床開發計劃的合理性。

同樣，其他製藥公司儘管早期結果令人鼓舞，但在後期臨床試驗中卻面臨重大挫折。

新藥開發過程中的任何階段都可能失敗。早期臨床試驗的結果不一定代表後期臨床試驗的結果，根據患者群的不同，後期臨床試驗的結果可能會大不相同。因此，新興療法的這些挫折是市場成長的主要障礙。

  • 獲得批准的障礙
  • 生活方式和飲食改變的建議
  • 臨床試驗結果不理想；

高三酸甘油脂血症 (HTG) | 疾病概述

  • 介紹
  • 症狀
  • 原因

高三酸甘油脂血症（HTG）的病因可分為遺傳性疾病（原發性疾病）和其他疾病引起的繼發性疾病。

脂蛋白脂肪酶(LPL) 缺乏症和載脂蛋白(Apo) C-II 缺乏症是兩種獨特的遺傳性疾病，在嬰兒期表現為乳糜微粒血症綜合徵，並導致兒童期高三酸甘油酯血症。在成人中，空腹濃度極高的乳糜微粒、極低密度脂蛋白 (VLDL) 碎片通常表示有嚴重的 HTG。

HTG 最常見的繼發性原因包括肥胖、未經治療的糖尿病、飲酒、懷孕和各種藥物治療。許多這些次要原因與胰島素反應異常有關。

  • 診斷

高三酸甘油脂血症（HTG）透過空腹血脂檢查來診斷。根據National Cholesterol Education Program Adult Treatment Panel III（NCEP ATP III）指南，HTG 可以是輕度(150-199 mg/dL)、高(200-499 mg/dL) 或非常高(>=500 mg/dL) 。

當三酸甘油酯高於 400 mg/dL 時，通常使用 Friedewald 公式估算 LDL-C 值，但這可能會低估 LDL-C。或者，可以考慮直接測量非 HDL-C（總膽固醇減去 HDL 膽固醇）或 LDL-C。

評估 LDL 大小和密度不被認為有利於 HTG 心血管事件的管理。ApoB 和 Lp(a) 水準有助於評估心血管風險。治療方法包括有效降低 Apo B 水平，菸鹼酸和雌激素可以降低 Lp(a)。然而，沒有確切的證據顯示降低 Lp(a) 可以預防動脈粥狀硬化性心血管疾病。

Lp(a) 水平升高與早發性心血管疾病相關，高 Lp(a) 水平證明積極的 LDL 管理是合理的。由於胰島素阻抗，肝脂肪變性或非酒精性脂肪性肝炎 (NASH) 常與高血壓並存。肝功能測試中轉氨酶升高建議進一步評估，包括肝臟超音波檢查。

  • 治療

競爭考慮

全球高三酸甘油脂血症 (HTG) 市場的主要參與者

  • Arrowhead Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • 89Bio Inc
  • Rivus Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • MediciNova Inc
  • Matinas BioPharma Holdings Inc

我們提供 10% 免費客製化和 3 個月的分析師支援。

常見問題（FAQ）：

  • 兒童會罹患高三酸甘油脂血症（HTG）嗎？

答：是的，兒童有可能患有高三酸甘油脂血症 (HTG)。高三酸甘油脂血症 (HTG) 可能會發生，特別是如果您有血脂異常家族史、久坐的生活方式或不健康的飲食。早期發現和介入對於預防長期健康併發症非常重要。

  • 高三酸甘油脂血症和高膽固醇血症一樣嗎？

答：不，雖然它們是相關的，但高三酸甘油酯血症特指血液中三酸甘油酯水平升高。高膽固醇血症是指LDL（低密度脂蛋白）膽固醇含量過高，俗稱壞膽固醇，也是心血管疾病的危險因子。

目錄

第一章簡介

第 2 章 高三酸甘油脂血症 (HTG)：概述

第三章概述

  • 介紹
  • 高三酸甘油脂血症 (HTG) 的分類
  • 富含三酸甘油酯的脂蛋白的代謝
  • 病因和危險因子
  • 臨床症狀
  • 診斷
    • 鑑別診斷
  • 治療和管理

第四章市場動態

  • 主要驅動因素
    • 提高對高三酸甘油脂血症（HTG）的認識
    • 高三酸甘油脂血症 (HTG) 盛行率增加
    • 擴大治療選擇
  • 主要限制因素
    • 新療法開發的回歸
    • 獲得監管部門批准的障礙
    • 改善生活習慣和飲食習慣的建議
    • 臨床試驗結果不理想

第五章管道處理

  • 目前管道概述
  • 比較分析：各階段產品

第六章治療評估：有效的產品

  • 依給藥途徑評價
  • 依階段和給藥途徑進行評價
  • 依分子類型評估
  • 依階段/分子類型評估

第七章 後期產品（第三期）

  • 比較分析
  • OLEZARSEN：IONIS PHARMACEUTICALS INC
    • 產品描述
    • 研究與開發
  • MND 2119：MOCHIDA PHARMACEUTICAL
    • 產品描述
    • 研究與開發
  • PEGOZAFERMIN：89BIO
    • 產品描述
    • 研究與開發
    • 安全性/有效性

第八章 中期產品（二期）

  • 比較分析
  • PLOZASIRAN：ARROWHEAD PHARMACEUTICALS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • EVINACUMAB：REGENERON PHARMACEUTICALS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • SEFA-1024：NORTHSEA THERAPEUTICS
    • 產品描述
    • 研究與開發
  • HU-6：RIVUS PHARMACEUTICALS
    • 產品描述
  • MAT-9001：MATINAS BIOPHARMA
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • MN-001：MEDICINOVA
    • 產品描述
    • 研究與開發
  • INV-202：NOVO NORDISK
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品開發活動
  • HTD1801：HIGHTIDE BIOPHARMA
    • 產品描述
  • MET-3：NUBIYOTA
    • 產品描述

第九章 早期產品（I/II期）

  • 比較分析
  • MAR-001：MAREA THERAPEUTICS
    • 產品描述
    • 研究與開發

第 10 章早期產品（第一階段）

  • 比較分析
  • LY 3875383：ELI LILLY AND COMPANY
    • 產品描述
    • 研究與開發
  • VSA-003：VISIRNA THERAPEUTICS
    • 產品描述
    • 研究與開發
  • GC 304：GENECRADLE THERAPEUTICS
    • 產品描述
    • 研究與開發
  • TLC-2716：ORSOBIO INC
    • 產品描述
    • 研究與開發
    • 產品開發活動
  • LIPISENSE：LIPIGON PHARMACEUTICALS
    • 產品描述
    • 研發內容
    • 安全性/有效性

第十一章 臨床前階段產品

  • 比較分析
  • STP125G：SIRNAOMICS
    • 產品描述
  • IMBP 001：IMETABOLIC BIOPHARMA
    • 產品描述
    • 產品/開發活動
  • STP251G：SIRNAOMICS
    • 產品描述
  • STP237G：SIRNAOMICS
    • 產品描述
  • SEFA 6131：NORTHSEA THERAPEUTICS
    • 產品描述
  • VK1430：VIKING THERAPEUTICS
    • 產品描述

第 12 章發現階段產品

  • 比較分析
  • ANGPTL3/8 ANTIBODY PROGRAM：KYTTARO
    • 產品描述
    • 產品開發活動
  • IMBP 150：IMETABOLIC BIOPHARMA
    • 產品描述

第 13 章非活躍產品

  • 比較分析

第十四章 策略發展

  • 合併/收購
  • 合夥/合約

第15章未滿足的需求

Product Code: 90768

KEY FINDINGS

Hypertriglyceridemia (HTG) is a condition marked by high triglyceride levels in the blood. Triglycerides, a type of fat, are sourced from dietary intake and produced by the body. Elevated triglyceride levels pose risks for cardiovascular diseases like heart disease and stroke.

Additionally, hypertriglyceridemia correlates with obesity, poorly controlled diabetes, hypothyroidism, liver or kidney disease, and specific genetic disorders. Lifestyle factors such as high-fat diets, excessive alcohol consumption, and physical inactivity can elevate triglycerides. Treatment includes dietary changes, weight management, regular exercise, and medication as necessary.

MARKET INSIGHTS

Key growth enablers of the global hypertriglyceridemia market:

  • Heightened awareness of hypertriglyceridemia
  • Growing prevalence of hypertriglyceridemia
  • Widening range of treatment options

Hypertriglyceridemia can be managed through lifestyle changes such as reducing fat and carbohydrate intake, limiting alcohol, quitting smoking, and regular exercise.

Moreover, therapeutic approaches such as statins and fibrates are employed to reduce triglyceride (TG) levels. Currently, statins and fibrates represent the main pharmacological therapies for hypertriglyceridemia (HTG). However, certain patients may be ineligible for or may not respond to these treatments.

To address this gap, companies are developing new therapeutic approaches aimed at more effectively reducing triglycerides in the bloodstream and mitigating the impact of HTG. Notably, approaches targeting apolipoprotein C-III and ANGPTL are being extensively explored.

In parallel, emerging drugs based on apolipoprotein C-III have shown promising results and are expected to reach the market in the near future. The anticipated launch of these innovative treatments could significantly advance HTG management, providing improved options for patients resistant to current therapies.

Key growth restraining factors of the global hypertriglyceridemia market:

  • Setbacks in new treatment development

Drug and product development for HTG is facing a high rate of clinical trial failures, occurring in the early phases and the later stages of development.

In line with this, Pfizer and Ionis recently discontinued the Phase III drug Vupanorsen after Phase II results did not justify continuing the clinical development program.

Similarly, other pharmaceutical companies have faced significant setbacks in late-stage clinical trials, even after promising outcomes in earlier stages.

Failures can arise at any stage during the development of emerging drugs. Initial clinical trial outcomes are not always indicative of later-stage results, and they can vary significantly across different patient cohorts. Hence, these setbacks with emerging therapies represent a significant barrier to market growth.

  • Obstacles in gaining regulatory approval
  • Recommendation for lifestyle and dietary changes
  • Suboptimal results from clinical trials

Hypertriglyceridemia | Disease Overview

  • Introduction
  • Symptoms
  • Causes

The causes of hypertriglyceridemia can be divided into genetically based disorders (primary disorders) and secondary disorders caused by other conditions.

Lipoprotein lipase (LPL) deficiency and Apolipoprotein (Apo) C-II deficiency are two well-characterized genetic forms of HTG occurring in infancy as chylomicronemia syndromes, leading to early childhood HTG. In adults, severe HTG is often indicated by extremely high fasting levels of chylomicrons, very low-density lipoproteins (VLDL), and remnants.

Among the most common secondary causes of HTG are obesity, untreated diabetes mellitus, alcohol consumption, pregnancy, and various medications. Many of these secondary causes are associated with abnormalities in insulin responsiveness.

  • Diagnosis

Hypertriglyceridemia (HTG) is diagnosed via a fasting lipid panel. As per the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines, HTG is classified based on triglyceride levels: mild (150-199 mg/dL), high (200-499 mg/dL), and very high (>=500 mg/dL).

When triglycerides exceed 400 mg/dL, LDL-C levels are often estimated using the Friedewald equation, which may underestimate LDL-C. Alternatively, non-HDL-C (total cholesterol minus HDL cholesterol) or direct LDL-C measurement can be considered.

Assessing LDL size or density is not considered beneficial for managing cardiovascular events in HTG. Apo B and Lp(a) levels may assist in assessing cardiovascular risk. Therapeutic options include effectively lowering Apo B levels, while niacin and estrogen may reduce Lp(a). However, evidence does not conclusively support that reducing Lp(a) prevents atherosclerotic cardiovascular disease.

High Lp(a) levels correlate with premature cardiovascular disease, warranting aggressive LDL management when Lp(a) levels are elevated. Hepatic steatosis or non-alcoholic steatohepatitis (NASH) often coexists with HTG due to insulin resistance. Elevated aminotransferases in liver function tests suggest further evaluation, including liver ultrasound.

  • Treatment

COMPETITIVE INSIGHTS

Major players in the global hypertriglyceridemia market:

  • Arrowhead Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • 89Bio Inc
  • Rivus Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • MediciNova Inc
  • Matinas BioPharma Holdings Inc

Arrowhead Pharmaceuticals Inc (Arrowhead) is a biotechnology company specializing in the development and commercialization of gene silencing therapeutics. The company employs RNA chemistries and its proprietary TRiM platform to target and silence genes that cause diseases. Arrowhead's product pipeline includes ARO-AAT, GSK4532990, ARO-ANG3, ARO-APOC3, ARO-PNPLA3, ARO-C3, ARO-ENaC2, ARO-MUC5AC, ARO-RAGE, ARO-COV, ARO-DUX4, ARO-MMP7, JNJ-3989, ARO-SOD1, HZN-457, and Olpasiran. These therapeutics address various conditions, including hypertriglyceridemia, dyslipidemia, facioscapulohumeral muscular dystrophy, complement-mediated diseases, and muco-obstructive or inflammatory pulmonary conditions. They also target liver disease, idiopathic pulmonary fibrosis, gout, cardiovascular disease, and chronic hepatitis B. Moreover, Arrowhead operates laboratory facilities in San Diego, California, and Madison, Wisconsin, with its headquarters located in Pasadena, California, United States.

The company is developing Plozasiran, a drug designed to reduce the production of Apolipoprotein C-III (apoC-III). ApoC-III is a key component of triglyceride-rich lipoproteins (TRLs) such as VLDL and chylomicrons, and it is fundamental in regulating triglyceride metabolism. The company anticipates that reducing hepatic production of apoC-III could potentially decrease VLDL synthesis and assembly, enhance the breakdown of TRLs, and improve the clearance of VLDL and chylomicron remnants. Plozasiran is presently undergoing Phase II clinical trials for treating severe hypertriglyceridemia.

We Offer 10% Free Customization and 3 Months Analyst Support

Frequently Asked Questions (FAQs):

  • Can children have hypertriglyceridemia?

A: Yes, children can also develop hypertriglyceridemia, especially if they have a family history of lipid disorders or if they lead sedentary lifestyles and consume unhealthy diets. Early detection and intervention are crucial to prevent long-term health complications.

  • Is hypertriglyceridemia the same as high cholesterol?

A: No, while related, hypertriglyceridemia specifically denotes elevated levels of triglycerides in the bloodstream. High cholesterol typically refers to elevated levels of LDL (low-density lipoprotein) cholesterol, commonly known as bad cholesterol, which also poses a risk factor for cardiovascular disease.

TABLE OF CONTENTS

1. INTRODUCTION TO THE REPORT

2. HYPERTRIGLYCERIDEMIA: SUMMARY

3. OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. CLASSIFICATION OF HYPERTRIGLYCERIDEMIA (HTG)
  • 3.3. METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS
  • 3.4. ETIOLOGY AND RISK FACTORS
  • 3.5. CLINICAL SIGNS AND SYMPTOMS
  • 3.6. DIAGNOSIS
    • 3.6.1. DIFFERENTIAL DIAGNOSIS
  • 3.7. TREATMENT AND MANAGEMENT

4. MARKET DYNAMICS

  • 4.1. KEY DRIVERS
    • 4.1.1. HEIGHTENED AWARENESS OF HYPERTRIGLYCERIDEMIA
    • 4.1.2. GROWING PREVALENCE OF HYPERTRIGLYCERIDEMIA
    • 4.1.3. WIDENING RANGE OF TREATMENT OPTIONS
  • 4.2. KEY RESTRAINTS
    • 4.2.1. SETBACKS IN NEW TREATMENT DEVELOPMENT
    • 4.2.2. OBSTACLES IN GAINING REGULATORY APPROVAL
    • 4.2.3. RECOMMENDATION FOR LIFESTYLE AND DIETARY CHANGES
    • 4.2.4. SUBOPTIMAL RESULTS FROM CLINICAL TRIALS

5. PIPELINE THERAPEUTICS

  • 5.1. CURRENT PIPELINE OVERVIEW
  • 5.2. COMPARATIVE ANALYSIS: PRODUCTS IN VARIOUS PHASES

6. THERAPEUTIC ASSESSMENT: ACTIVE PRODUCTS

  • 6.1. EVALUATION BY ROUTE OF ADMINISTRATION
  • 6.2. EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • 6.3. EVALUATION BY MOLECULE TYPE
  • 6.4. EVALUATION BY STAGE AND MOLECULE TYPE

7. LATE-STAGE PRODUCTS (PHASE III)

  • 7.1. COMPARATIVE ANALYSIS
  • 7.2. OLEZARSEN: IONIS PHARMACEUTICALS INC
    • 7.2.1. PRODUCT DESCRIPTION
    • 7.2.2. RESEARCH AND DEVELOPMENT
  • 7.3. MND 2119: MOCHIDA PHARMACEUTICAL
    • 7.3.1. PRODUCT DESCRIPTION
    • 7.3.2. RESEARCH AND DEVELOPMENT
  • 7.4. PEGOZAFERMIN: 89BIO
    • 7.4.1. PRODUCT DESCRIPTION
    • 7.4.2. RESEARCH AND DEVELOPMENT
    • 7.4.3. SAFETY AND EFFICACY

8. MID-STAGE PRODUCTS (PHASE II)

  • 8.1. COMPARATIVE ANALYSIS
  • 8.2. PLOZASIRAN: ARROWHEAD PHARMACEUTICALS
    • 8.2.1. PRODUCT DESCRIPTION
    • 8.2.2. RESEARCH AND DEVELOPMENT
    • 8.2.3. SAFETY AND EFFICACY
  • 8.3. EVINACUMAB: REGENERON PHARMACEUTICALS
    • 8.3.1. PRODUCT DESCRIPTION
    • 8.3.2. RESEARCH AND DEVELOPMENT
    • 8.3.3. SAFETY AND EFFICACY
  • 8.4. SEFA-1024: NORTHSEA THERAPEUTICS
    • 8.4.1. PRODUCT DESCRIPTION
    • 8.4.2. RESEARCH AND DEVELOPMENT
  • 8.5. HU-6: RIVUS PHARMACEUTICALS
    • 8.5.1. PRODUCT DESCRIPTION
  • 8.6. MAT-9001: MATINAS BIOPHARMA
    • 8.6.1. PRODUCT DESCRIPTION
    • 8.6.2. RESEARCH AND DEVELOPMENT
    • 8.6.3. SAFETY AND EFFICACY
  • 8.7. MN-001: MEDICINOVA
    • 8.7.1. PRODUCT DESCRIPTION
    • 8.7.2. RESEARCH AND DEVELOPMENT
  • 8.8. INV-202: NOVO NORDISK
    • 8.8.1. PRODUCT DESCRIPTION
    • 8.8.2. RESEARCH AND DEVELOPMENT
    • 8.8.3. SAFETY AND EFFICACY
    • 8.8.4. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 8.9. HTD1801: HIGHTIDE BIOPHARMA
    • 8.9.1. PRODUCT DESCRIPTION
  • 8.10. MET-3: NUBIYOTA
    • 8.10.1. PRODUCT DESCRIPTION

9. EARLY-STAGE PRODUCTS (PHASE I/II)

  • 9.1. COMPARATIVE ANALYSIS
  • 9.2. MAR-001: MAREA THERAPEUTICS
    • 9.2.1. PRODUCT DESCRIPTION
    • 9.2.2. RESEARCH AND DEVELOPMENT

10. EARLY-STAGE PRODUCTS (PHASE I)

  • 10.1. COMPARATIVE ANALYSIS
  • 10.2. LY 3875383: ELI LILLY AND COMPANY
    • 10.2.1. PRODUCT DESCRIPTION
    • 10.2.2. RESEARCH AND DEVELOPMENT
  • 10.3. VSA-003: VISIRNA THERAPEUTICS
    • 10.3.1. PRODUCT DESCRIPTION
    • 10.3.2. RESEARCH AND DEVELOPMENT
  • 10.4. GC 304: GENECRADLE THERAPEUTICS
    • 10.4.1. PRODUCT DESCRIPTION
    • 10.4.2. RESEARCH AND DEVELOPMENT
  • 10.5. TLC-2716: ORSOBIO INC
    • 10.5.1. PRODUCT DESCRIPTION
    • 10.5.2. RESEARCH AND DEVELOPMENT
    • 10.5.3. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 10.6. LIPISENSE: LIPIGON PHARMACEUTICALS
    • 10.6.1. PRODUCT DESCRIPTION
    • 10.6.2. RESEARCH AND DEVELOPMENT
    • 10.6.3. SAFETY AND EFFICACY

11. PRECLINICAL-STAGE PRODUCTS

  • 11.1. COMPARATIVE ANALYSIS
  • 11.2. STP125G: SIRNAOMICS
    • 11.2.1. PRODUCT DESCRIPTION
  • 11.3. IMBP 001: IMETABOLIC BIOPHARMA
    • 11.3.1. PRODUCT DESCRIPTION
    • 11.3.2. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.4. STP251G: SIRNAOMICS
    • 11.4.1. PRODUCT DESCRIPTION
  • 11.5. STP237G: SIRNAOMICS
    • 11.5.1. PRODUCT DESCRIPTION
  • 11.6. SEFA 6131: NORTHSEA THERAPEUTICS
    • 11.6.1. PRODUCT DESCRIPTION
  • 11.7. VK1430: VIKING THERAPEUTICS
    • 11.7.1. PRODUCT DESCRIPTION

12. DISCOVERY-STAGE PRODUCTS

  • 12.1. COMPARATIVE ANALYSIS
  • 12.2. ANGPTL3/8 ANTIBODY PROGRAM: KYTTARO
    • 12.2.1. PRODUCT DESCRIPTION
    • 12.2.2. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 12.3. IMBP 150: IMETABOLIC BIOPHARMA
    • 12.3.1. PRODUCT DESCRIPTION

13. INACTIVE PRODUCTS

  • 13.1. COMPARATIVE ANALYSIS

14. STRATEGIC DEVELOPMENTS

  • 14.1. MERGERS & ACQUISITIONS
  • 14.2. PARTNERSHIPS & AGREEMENTS

15. UNMET NEEDS

LIST OF TABLES

  • TABLE 1: PRIMARY (GENETIC) DISORDERS CAUSING SEVERE HTG
  • TABLE 2: TOTAL ACTIVE PRODUCTS IN HYPERTRIGLYCERIDEMIA PIPELINE
  • TABLE 3: PRODUCTS IN VARIOUS PHASES
  • TABLE 4: EVALUATION BY ROUTE OF ADMINISTRATION
  • TABLE 5: EVALUATION BY MOLECULE TYPE
  • TABLE 6: LATE-STAGE PRODUCTS (PHASE III)
  • TABLE 7: CLINICAL TRIALS DESCRIPTION: OLEZARSEN
  • TABLE 8: GENERAL DESCRIPTION: OLEZARSEN
  • TABLE 9: CLINICAL TRIALS DESCRIPTION: MND 2119
  • TABLE 10: GENERAL DESCRIPTION: MND 2119
  • TABLE 11: CLINICAL TRIALS DESCRIPTION: PEGOZAFERMIN
  • TABLE 12: GENERAL DESCRIPTION: PEGOZAFERMIN
  • TABLE 13: MID-STAGE PRODUCTS (PHASE II)
  • TABLE 14: CLINICAL TRIALS DESCRIPTION: PLOZASIRAN
  • TABLE 15: GENERAL DESCRIPTION: PLOZASIRAN
  • TABLE 16: CLINICAL TRIALS DESCRIPTION: EVINACUMAB
  • TABLE 17: GENERAL DESCRIPTION: EVINACUMAB
  • TABLE 18: CLINICAL TRIALS DESCRIPTION: SEFA 1024
  • TABLE 19: GENERAL DESCRIPTION: SEFA 1024
  • TABLE 20: GENERAL DESCRIPTION: HU-6
  • TABLE 21: CLINICAL TRIALS DESCRIPTION: MAT-9001
  • TABLE 22: GENERAL DESCRIPTION: MAT-9001
  • TABLE 23: CLINICAL TRIALS DESCRIPTION: MN-001
  • TABLE 24: GENERAL DESCRIPTION: MN-001
  • TABLE 25: CLINICAL TRIALS DESCRIPTION: INV-202
  • TABLE 26: GENERAL DESCRIPTION: INV-202
  • TABLE 27: GENERAL DESCRIPTION: HTD1801
  • TABLE 28: GENERAL DESCRIPTION: MET-3
  • TABLE 29: EARLY-STAGE PRODUCTS (PHASE I/II)
  • TABLE 30: CLINICAL TRIALS DESCRIPTION: MAR001
  • TABLE 31: GENERAL DESCRIPTION: MAR001
  • TABLE 32: EARLY-STAGE PRODUCTS (PHASE I)
  • TABLE 33: CLINICAL TRIALS DESCRIPTION: LY3875383
  • TABLE 34: GENERAL DESCRIPTION: LY3875383
  • TABLE 35: CLINICAL TRIALS DESCRIPTION: VSA003
  • TABLE 36: GENERAL DESCRIPTION: VSA003
  • TABLE 37: CLINICAL TRIALS DESCRIPTION: GC304
  • TABLE 38: GENERAL DESCRIPTION: GC304
  • TABLE 39: CLINICAL TRIALS DESCRIPTION: TLC-2716
  • TABLE 40: GENERAL DESCRIPTION: TLC-2716
  • TABLE 41: GENERAL DESCRIPTION: LIPISENSE
  • TABLE 42: PRECLINICAL-STAGE PRODUCTS
  • TABLE 43: GENERAL DESCRIPTION: STP125G
  • TABLE 44: GENERAL DESCRIPTION: IMBP 001
  • TABLE 45: GENERAL DESCRIPTION: STP251G
  • TABLE 46: GENERAL DESCRIPTION: STP237G
  • TABLE 47: GENERAL DESCRIPTION: SEFA 6131
  • TABLE 48: GENERAL DESCRIPTION: VK1430
  • TABLE 49: DISCOVERY-STAGE PRODUCTS
  • TABLE 50: GENERAL DESCRIPTION: ANGPTL3/8 ANTIBODY PROGRAM
  • TABLE 51: GENERAL DESCRIPTION: IMBP 150
  • TABLE 52: INACTIVE-STAGE PRODUCTS
  • TABLE 53: LIST OF MERGERS & ACQUISITIONS
  • TABLE 54: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

  • FIGURE 1: CLASSIFICATION OF HTG BASED ON SERUM TG LEVEL
  • FIGURE 2: KEY STEPS INVOLVED IN THE METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS
  • FIGURE 3: METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS (TGRL)
  • FIGURE 4: CAUSES OF HTG
  • FIGURE 5: THE INTERTWINED CONTRIBUTING FACTORS AND CLOSE INTERACTIONS BETWEEN HTG, TYPE II DIABETES, AND ACUTE PANCREATITIS
  • FIGURE 6: SIGNS AND SYMPTOMS OF HTG
  • FIGURE 7: PRODUCTS IN VARIOUS PHASES
  • FIGURE 8: EVALUATION BY ROUTE OF ADMINISTRATION
  • FIGURE 9: EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • FIGURE 10: EVALUATION BY MOLECULE TYPE
  • FIGURE 11: EVALUATION BY STAGE AND MOLECULE TYPE
  • FIGURE 12: LATE-STAGE PRODUCTS (PHASE III)
  • FIGURE 13: MID-STAGE PRODUCTS (PHASE II)
  • FIGURE 14: EARLY-STAGE PRODUCTS (PHASE I/II)
  • FIGURE 15: EARLY-STAGE PRODUCTS (PHASE I)
  • FIGURE 16: PRECLINICAL-STAGE PRODUCTS
  • FIGURE 17: DISCOVERY-STAGE PRODUCTS
  • FIGURE 18: INACTIVE STAGE PRODUCTS